Table 3.
Geometric Mean Titers and Geometric Mean Titer Ratio of the Antigen-Specific Immunoglobulin (in BAU/mL).
| Parameter | Vaccine |
GMT ratio; (95 % CI) | p-value | |
|---|---|---|---|---|
| AZD1222 | MVC-COV1901 | |||
| Seropositive | ||||
| n | 294 | 264 | ||
| Baseline | ||||
| GMT | 57.8 | 56.8 | ||
| 95 %CI | 50.4–66.2 | 49.7–64.9 | ||
| Day 14 after 2nd shot | ||||
| GMT | 1617.7 | 2812.9 | 1.7 | <0.0001 |
| 95 %CI | 1460.9–1791.3 | 2575.4–3072.2 | (1.5–1.99) | |
| GMFR | 28.0 | 49.5 | ||
| 95 % CI | 23.6–33.2 | 42.2–58.1 | ||
| Seronegative | ||||
| n | 146 | 180 | ||
| Baseline | ||||
| GMT | 4.6 | 4.6 | ||
| 95 %CI | 4.6–4.6 | 4.6–4.6 | ||
| Day 14 after 2nd shot | ||||
| GMT | 231.5 | 1091.8 | 4.7 | <0.0001 |
| 95 %CI | 196.7–272.4 | 945.7–1260.5 | (3.8–5.9) | |
| GMFR | 50.8 | 239.4 | ||
| 95 % CI | 43.2–59.7 | 207.5–276.3 | ||
Abbreviation: n = no. of participants, CI = confidence interval, GMT = geometric mean titer, GMFR = geometric mean fold rise.
Note: [1] GMT ratio was computed as, GMTMVC-COV1901/GMTAZD1222.
[2] p-value based on two-sample t test or Wilcoxon rank sum test.